Casgevy Expands to Children as Young as 2 — What the CRISPR Milestone Actually Means

On July 1, 2026, the FDA expanded the approved use of Casgevy (exagamglogene autotemcel, or "exa-cel") to patients as young as 2 years old — making it the first gene therapy for sickle cell disease approved for children under 12. It's a genuinely significant milestone, both medically and as a test case for how CRISPR-based medicine scales beyond its first approval.

What actually changed

Casgevy isn't new — Vertex Pharmaceuticals and CRISPR Therapeutics won the original FDA approval in December 2023, making it the first CRISPR/Cas9 gene-editing therapy ever cleared for human use. That initial approval covered sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in patients 12 and older. This week's decision — announced well ahead of the FDA's target review date — extends both indications down to age 2.

That age expansion matters more than it might sound. Sickle cell disease causes cumulative, often irreversible organ damage — strokes, kidney disease, avascular necrosis — that compounds with every year a patient goes untreated. A therapy that can only be given at 12 has already let a decade of damage accumulate. Being able to treat a 2-year-old means intervening before much of that damage occurs, not after.

How it actually works

Casgevy is an ex vivo therapy: doctors extract a patient's own blood stem cells, use CRISPR/Cas9 to edit a specific regulatory region near the BCL11A gene, and infuse the edited cells back after conditioning chemotherapy. The edit reduces BCL11A activity, which in turn de-represses fetal hemoglobin production — the version of hemoglobin the body normally silences after infancy. Elevated fetal hemoglobin compensates for the defective adult hemoglobin that causes sickling, reducing or eliminating vaso-occlusive crises.

It's a one-time treatment, not a chronic therapy — which is the central argument for its price tag and also the central question mark on its economics.

The economics: $2.2 million, and slow to scale

Casgevy carries a list price of $2.2 million per patient (its rival, bluebird bio's Lyfgenia, lists at $3.1 million). CRISPR Therapeutics has said it sees an addressable global market of roughly 60,000 patients at that price point — a large theoretical number, but actual uptake has been slow and methodical rather than explosive.

As of CRISPR Therapeutics' most recent quarterly update, more than 500 people globally have initiated the Casgevy treatment journey, and the companies reported $43 million in first-quarter 2026 Casgevy revenue. Vertex is projecting roughly $500 million in combined 2026 revenue from Casgevy and its newly approved non-opioid pain therapy, Journavx — real but still modest numbers for a therapy addressing a many-billion-dollar theoretical market. The bottleneck isn't demand; it's the treatment infrastructure. Casgevy requires specialized cell-collection, editing, and stem-cell transplant capacity that only a limited number of authorized treatment centers currently have, plus payer sign-off on a seven-figure single payment.

The skeptical read

This is a real approval with real clinical benefit behind it — the original pivotal trial data showed the large majority of treated patients free of vaso-occlusive crises for at least a year post-treatment, and pediatric expansion trial data supported this week's decision. It is not, however, evidence that CRISPR medicine has "arrived" as a scalable category. Three years after the first approval, patient numbers remain in the hundreds, not thousands, and the treatment infrastructure bottleneck hasn't meaningfully loosened. Extending the label to 2-year-olds is a genuine clinical win for the patients who can access it. Whether the broader gene-editing field can solve the manufacturing, logistics, and payer-access problems that have kept uptake slow is still the open question — and the one worth watching more than any single label expansion.